Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Chinese Rare Disease Biotech IPO To Spark Interest In Less Travelled Path?

Executive Summary

CanBridge public listing is expected to generate much needed funding and spotlights a largely untapped but challenging segment.

You may also be interested in...



Winter Olympics Test China's 'Zero COVID' Limits, Treatment Constraints

Amid China’s increasingly inward-looking and dual circulation economic policies, the Beijing Winter Olympics provide rare insight into policymakers’ handling of a global event.

Soft Capsule, Hard Truth: Will Chugai Lawsuit Usher In New Era Of China Patent Linkage?

Few drug patent infringement cases go to court in China, where a murky and lengthy process deters many from pursuing litigation. But a newly enacted Patent Law with patent linkage provisions is spurring a rise in infringement lawsuits, with one recent case involving a major Japanese pharma firm underscoring the remaining challenges.

China Gene Therapy Developers Rush To Clinic In 'Winner Takes All' Battle

Gene therapies for conditions ranging from hemophilia to retinal diseases are blossoming in China and the race in which the winner may take all is on. Driven by ready investors, the field is on the cusp of becoming the latest innovation battleground in the country, while some developers are already moving ahead in the US.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145581

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel